Perspective Therapeutics (CATX) vs Profound Medical (PROF)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Profound Medical (PROF) has outperformed Perspective Therapeutics (CATX) over the past year, gaining 4.1% versus a loss of 31.1%. Over five years, PROF leads with a -54.0% price change compared with -57.1% for CATX. Perspective Therapeutics is the larger company by market cap ($303.6 million vs $252.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | PROF |
|---|---|---|
| Share price | $2.66 | $6.90 |
| Market cap | $303.64M | $252.13M |
| 1-day change | -1.85% | -0.14% |
| YTD return | -3.27% | -12.33% |
| 1-year return | -31.09% | +4.07% |
| 5-year return | -57.10% | -53.96% |
| EPS (TTM) | $-1.33 | $-0.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.16 | $8.95 |
| 52-week low | $1.96 | $4.80 |
| Distance from 52-week high | -56.82% | -22.91% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +362.03% | +61.45% |
| Average volume | 1.65M | 168.50K |
| Shares outstanding | 114.15M | 36.54M |
| Employees | 163 | 162 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PROF has outperformed CATX by 35.2 percentage points over the past year.
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Healthcare · Medical Devices · 163 employees
About Profound Medical
PROF stock →Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue.
Healthcare · Medical Devices · 162 employees
CATX vs PROF FAQ
Which is bigger, Perspective Therapeutics or Profound Medical?
Perspective Therapeutics (CATX) is larger, with a market capitalization of $303.64M compared with $252.13M for Profound Medical (PROF).
Which stock has performed better over the past year, CATX or PROF?
PROF returned +4.07% over the past 12 months, compared with -31.09% for CATX (price return, excluding dividends). Past performance does not predict future results.
Are Perspective Therapeutics and Profound Medical in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.